Ogasawara Takuto, Tanaka Toshiaki, Shindo Tetsuya, Hashimoto Kohei, Fukuta Fumimasa, Kobayashi Ko, Sugawara Taro, Hasegawa Tadashi, Masumori Naoya
Department of Urology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543 Japan.
Department of Surgical Pathology, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543 Japan.
Int Cancer Conf J. 2020 Jul 24;9(4):235-239. doi: 10.1007/s13691-020-00435-1. eCollection 2020 Oct.
We report two cases of muscle-invasive bladder cancer (MIBC) with increasing multiple osteoblastic bone lesions but shrinking other lesions in response to chemotherapy. Case 1 had MIBC and received radical cystectomy followed by adjuvant gemcitabine plus cisplatin chemotherapy (GC). Three years after, follow computed tomography (CT) showed development of multiple lymph node metastasis, and then we performed GC as a first-line systemic chemotherapy. After two cycles of GC, CT showed de novo multiple osteoblastic lesions although metastatic lymph nodes were shrunk. Biopsy of the sternum revealed metastatic urothelial carcinoma. Case 2 had MIBC with multiple osteoblastic lesions on CT and bone scintigraphy, which was initially diagnosed as cT3bN0M1. After one cycle of GC, the number of osteoblastic lesions obviously increased although bladder tumor was regressed. Since the clinical course was unusual, biopsy of the clavicle was done. The histological diagnosis was benign osteoblastic bone disease, then the clinical diagnosis was revised to non-metastatic MIBC, and radical cystectomy was performed. Ten months after surgery, the patients complained worsening backache and CT showed increase in number of osteoblastic lesions. Eventually, ilium biopsy revealed bone metastasis of urothelial carcinoma. In case of atypical finding and unusual clinical course, biopsy of suspected metastatic lesion may be informative although adequate sampling should be secured.
我们报告了两例肌肉浸润性膀胱癌(MIBC)患者,其在化疗后出现多发性成骨骨病变增多,但其他病变缩小。病例1患有MIBC,接受了根治性膀胱切除术,随后进行吉西他滨联合顺铂辅助化疗(GC)。三年后,随访计算机断层扫描(CT)显示出现多处淋巴结转移,然后我们将GC作为一线全身化疗方案。在两个周期的GC治疗后,CT显示出现新的多发性成骨病变,尽管转移性淋巴结缩小。胸骨活检显示为转移性尿路上皮癌。病例2患有MIBC,CT和骨闪烁显像显示有多处成骨病变,最初诊断为cT3bN0M1。在一个周期的GC治疗后,尽管膀胱肿瘤缩小,但成骨病变数量明显增加。由于临床过程不寻常,对锁骨进行了活检。组织学诊断为良性成骨骨病,随后临床诊断修订为非转移性MIBC,并进行了根治性膀胱切除术。手术后十个月,患者抱怨背痛加重,CT显示成骨病变数量增加。最终,髂骨活检显示为尿路上皮癌骨转移。在出现非典型表现和不寻常临床过程的情况下,尽管应确保足够的取样,但对疑似转移病变进行活检可能会提供有价值的信息。